View in EDS

A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.

Saved in:
Bibliographic Details
Title: A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
Authors: Suder, A.1 anetasuder@hotmail.com, Ang, J.E.2 jooern.ang@icr.ac.uk, Kyle, F.1 fiona.kyle@gstt.nhs.uk, Harris, D.3 dean.harris@cdhb.health.nz, Rudman, S.1 sarah.rudman@gstt.nhs.uk, Kristeleit, R.3 r.kristeleit@ucl.ac.uk, Solca, F.4 flavio.solca@boehringer-ingelheim.com, Uttenreuther-Fischer, M.5 martina.uttenreuther-fischer@boehringer-ingelheim.com, Pemberton, K.6 karine.pemberton@boehringer-ingelheim.com, Pelling, K.7 katy.pelling@boehringer-ingelheim.com, Schnell, D.8 david.schnell@boehringer-ingelheim.com, de Bono, J.2 johann.de-Bono@icr.ac.uk, Spicer, J.9 james.spicer@kcl.ac.uk
Source: European Journal of Cancer. Nov2015, Vol. 51 Issue 16, p2275-2284. 10p.
Database: Academic Search Ultimate
FullText Text:
  Availability: 0
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 110270837
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Suder%2C+A%2E%22">Suder, A.</searchLink><relatesTo>1</relatesTo><i> anetasuder@hotmail.com</i><br /><searchLink fieldCode="AR" term="%22Ang%2C+J%2EE%2E%22">Ang, J.E.</searchLink><relatesTo>2</relatesTo><i> jooern.ang@icr.ac.uk</i><br /><searchLink fieldCode="AR" term="%22Kyle%2C+F%2E%22">Kyle, F.</searchLink><relatesTo>1</relatesTo><i> fiona.kyle@gstt.nhs.uk</i><br /><searchLink fieldCode="AR" term="%22Harris%2C+D%2E%22">Harris, D.</searchLink><relatesTo>3</relatesTo><i> dean.harris@cdhb.health.nz</i><br /><searchLink fieldCode="AR" term="%22Rudman%2C+S%2E%22">Rudman, S.</searchLink><relatesTo>1</relatesTo><i> sarah.rudman@gstt.nhs.uk</i><br /><searchLink fieldCode="AR" term="%22Kristeleit%2C+R%2E%22">Kristeleit, R.</searchLink><relatesTo>3</relatesTo><i> r.kristeleit@ucl.ac.uk</i><br /><searchLink fieldCode="AR" term="%22Solca%2C+F%2E%22">Solca, F.</searchLink><relatesTo>4</relatesTo><i> flavio.solca@boehringer-ingelheim.com</i><br /><searchLink fieldCode="AR" term="%22Uttenreuther-Fischer%2C+M%2E%22">Uttenreuther-Fischer, M.</searchLink><relatesTo>5</relatesTo><i> martina.uttenreuther-fischer@boehringer-ingelheim.com</i><br /><searchLink fieldCode="AR" term="%22Pemberton%2C+K%2E%22">Pemberton, K.</searchLink><relatesTo>6</relatesTo><i> karine.pemberton@boehringer-ingelheim.com</i><br /><searchLink fieldCode="AR" term="%22Pelling%2C+K%2E%22">Pelling, K.</searchLink><relatesTo>7</relatesTo><i> katy.pelling@boehringer-ingelheim.com</i><br /><searchLink fieldCode="AR" term="%22Schnell%2C+D%2E%22">Schnell, D.</searchLink><relatesTo>8</relatesTo><i> david.schnell@boehringer-ingelheim.com</i><br /><searchLink fieldCode="AR" term="%22de+Bono%2C+J%2E%22">de Bono, J.</searchLink><relatesTo>2</relatesTo><i> johann.de-Bono@icr.ac.uk</i><br /><searchLink fieldCode="AR" term="%22Spicer%2C+J%2E%22">Spicer, J.</searchLink><relatesTo>9</relatesTo><i> james.spicer@kcl.ac.uk</i>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22European+Journal+of+Cancer%22">European Journal of Cancer</searchLink>. Nov2015, Vol. 51 Issue 16, p2275-2284. 10p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=110270837
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.ejca.2015.07.041
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 2275
    Titles:
      – TitleFull: A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Suder, A.
      – PersonEntity:
          Name:
            NameFull: Ang, J.E.
      – PersonEntity:
          Name:
            NameFull: Kyle, F.
      – PersonEntity:
          Name:
            NameFull: Harris, D.
      – PersonEntity:
          Name:
            NameFull: Rudman, S.
      – PersonEntity:
          Name:
            NameFull: Kristeleit, R.
      – PersonEntity:
          Name:
            NameFull: Solca, F.
      – PersonEntity:
          Name:
            NameFull: Uttenreuther-Fischer, M.
      – PersonEntity:
          Name:
            NameFull: Pemberton, K.
      – PersonEntity:
          Name:
            NameFull: Pelling, K.
      – PersonEntity:
          Name:
            NameFull: Schnell, D.
      – PersonEntity:
          Name:
            NameFull: de Bono, J.
      – PersonEntity:
          Name:
            NameFull: Spicer, J.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 11
              Text: Nov2015
              Type: published
              Y: 2015
          Identifiers:
            – Type: issn-print
              Value: 09598049
          Numbering:
            – Type: volume
              Value: 51
            – Type: issue
              Value: 16
          Titles:
            – TitleFull: European Journal of Cancer
              Type: main
ResultId 1